PLEASANTON, Calif.,
May 21, 2020 /PRNewswire-PRWeb/
-- NeoTract, a wholly owned subsidiary of Teleflex
Incorporated (NYSE:TFX) focused on addressing unmet needs in the
field of urology, today announced that Naveen Divakaruni, D.O., Advocate Medical Group
in Aurora, IL, has been designated
as a UroLift® Center of Excellence. The designation recognizes that
Dr. Divakaruni has achieved a high level of training and experience
with the UroLift® System and demonstrated a commitment to exemplary
care for men suffering from symptoms associated with Benign
Prostatic Hyperplasia (BPH), also known as enlarged prostate.
Recommended for the treatment of BPH in both the American
Urological Association and European Association of Urology clinical
guidelines, the FDA-cleared Prostatic Urethral Lift procedure using
the UroLift System is a proven, minimally invasive technology for
treating lower urinary tract symptoms due to BPH. The UroLift
permanent implants, delivered during a transurethral outpatient
procedure, relieve prostate obstruction and open the urethra
directly without cutting, heating, or removing prostate tissue.
The UroLift Center of Excellence program is designed to
highlight urologists who are committed to educating their patients
on BPH and the UroLift System as a treatment option and
consistently seek to deliver excellent patient outcomes and
experiences.
"This designation recognizes Dr. Naveen
Divakaruni as a UroLift Center of Excellence for his
commitment to providing safe and effective treatment to patients
with BPH," said Dave Amerson,
president of the Teleflex Interventional Urology business unit. "We
are pleased to see the continued acceptance of the UroLift System
as a standard of care treatment that may allow men to discontinue
the use of BPH medications and improve their quality of life."
Over 40 million men in the United
States are affected by BPH, a condition that occurs when the
prostate gland that surrounds the male urethra becomes enlarged
with advancing age and begins to obstruct the urinary system.
Symptoms of BPH often include interrupted sleep and urinary
problems and can cause loss of productivity, depression and
decreased quality of life.
Medication is often the first-line therapy for enlarged
prostate, but relief can be inadequate and temporary. Side effects
of medication treatment can include sexual dysfunction, dizziness
and headaches, prompting many patients to quit using the drugs. For
these patients, the classic alternative is surgery that cuts, heats
or removes prostate tissue to open the blocked urethra. While
current surgical options can be very effective in relieving
symptoms, they can also leave patients with permanent side effects
such as urinary incontinence, erectile dysfunction, and retrograde
ejaculation.
About the UroLift® System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants,
delivered during a minimally invasive transurethral outpatient
procedure, relieve prostate obstruction and open the urethra
directly without cutting, heating, or removing prostate tissue.
Clinical data from a pivotal 206-patient randomized controlled
study showed that patients with enlarged prostate receiving UroLift
implants reported rapid and durable symptomatic and urinary flow
rate improvement without compromising sexual function*1,2. Patients
also experienced a significant improvement in quality of life. Over
100,000 men have been treated with the UroLift System in the U.S.
Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most
symptoms were mild to moderate in severity and resolved within two
to four weeks after the procedure. The Prostatic Urethral Lift
procedure using the UroLift System is recommended for the treatment
of BPH in both the American Urological Association and European
Association of Urology clinical guidelines. The UroLift System is
available in the U.S., Europe,
Australia, Canada, Mexico and South
Korea. Learn more at http://www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the
Interventional Urology Business Unit is dedicated to developing
innovative, minimally invasive and clinically effective devices
that address unmet needs in the field of urology. Our initial focus
is on improving the standard of care for patients with BPH using
the UroLift System, a minimally invasive permanent implant system
that treats symptoms while preserving normal sexual function*1,2.
Learn more at http://www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people's lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit http://www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose
For Teleflex Incorporated: Jake
Elguicze, 610.948.2836
Treasurer and Vice President, Investor Relations
Media:
Nicole Osmer, 650.454.0504
nicole@healthandcommerce.com
*No instances of new, sustained erectile or ejaculatory
dysfunction 1. Roehrborn, J Urology 2013 LIFT Study
2.McVary, J Sex Med 2016
MAC00968-01 Rev A
SOURCE NeoTract Teleflex